Is Johnson and Johnson Stock (JNJ) a Good Investment? (2024)

Featured Tickers:

JNJ

Learn more about whether Johnson & Johnson is a good stock to buy or sell based on recent news as well as its key financial metrics. Read on to find out how (JNJ) grades on certain investment factors and determine whether it meets your investment needs.

Latest Johnson & Johnson Stock News

As of March 08, 2024, Johnson & Johnson had a $382.7 billion market capitalization, putting it in the 100th percentile of companies in the Pharmaceuticals industry.

Currently, Johnson & Johnson’s price-earnings ratio is 30.2. Johnson & Johnson’s trailing 12-month revenue is $85.2 billion with a 41.3% profit margin. Year-over-year quarterly sales growth most recently was 7.3%. Analysts expect adjusted earnings to reach $10.658 per share for the current fiscal year. Johnson & Johnson currently has a 3.0% dividend yield.

The outlook for the Pharmaceuticals sub-industry is positive as the world returns to normalcy and demand for electives and improved medical utilization. COVID-19 therapies, oncology and immunology are essential aspects of pharmaceutical companies. Should COVID-19 variants continue to arise getting a COVID-19 vaccine could become a seasonal phenomenon, much like the flu vaccine. If that were to happen, it would prove to be very lucrative for pharmaceutical companies, as it would generate recurring sales. Recent FDA recommendations, such as approval for a fourth booster dose for those aged 50 or older, suggests we may be moving in this direction. Generic drug makers are expected to continue to struggle due to lower-cost emerging market competition. Despite this, policy risks are on the rise. Lowering drug prices continues to be a bipartisan issue as both parties aim to offer Americans more affordable prices. While this provides uncertainty in the long-term, it is unlikely that legislation will get passed in the near future due to more pressing issues in the political agenda. Year to date through June 3, the S&P Pharmaceuticals Index was up 1.5% vs. a 13.6% decline for the S&P Composite 1500 Index. In 2021, the S&P Pharmaceuticals Index returned a gain of 21.8%, vs. a gain of 26.7% for the S&P Composite 1500.

Sign Up to Receive a Free Special Report That Shows How A+ Investor Grades Can Help You Make Investment Decisions

Grading Johnson & Johnson Stock

Before you choose to buy, sell or hold Johnson & Johnson stock, you’ll want to analyze how it has been graded. Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, making sense of financial ratios, reading income statements and analyzing recent stock movement. To help individual investors decide whether or not to buy (JNJ) stock, AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way that is suitable for investors of all knowledge levels.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A–F grades for each of five key investing factors: value, growth, momentum, earnings revisions and quality. Here, we’ll take a closer look at Johnson & Johnson’s stock grades for value, growth and quality. Learn more about A+ Investor here!

Johnson & Johnson Stock Value Grade

Value Grade:

Metric Rank JNJ Sector Median
Price/Sales 79 4.51 3.40
Price/Earnings 70 30.2 30.2
EV/EBITDA 62 12.9 11.2
Shareholder Yield 7 10.9% (5.0%)
Price/Book Value 84 5.58 2.26
Price/Free Cash Flow 86 61.2 24.8

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade is derived from a stock’s value score. The value score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

Johnson & Johnson has a Value Score of 25, which is Expensive.

Latest Johnson & Johnson Stock News

As of March 08, 2024, Johnson & Johnson had a $382.7 billion market capitalization, putting it in the 100th percentile of companies in the Pharmaceuticals industry.

Currently, Johnson & Johnson’s price-earnings ratio is 30.2. Johnson & Johnson’s trailing 12-month revenue is $85.2 billion with a 41.3% profit margin. Year-over-year quarterly sales growth most recently was 7.3%. Analysts expect adjusted earnings to reach $10.658 per share for the current fiscal year. Johnson & Johnson currently has a 3.0% dividend yield.

The outlook for the Pharmaceuticals sub-industry is positive as the world returns to normalcy and demand for electives and improved medical utilization. COVID-19 therapies, oncology and immunology are essential aspects of pharmaceutical companies. Should COVID-19 variants continue to arise getting a COVID-19 vaccine could become a seasonal phenomenon, much like the flu vaccine. If that were to happen, it would prove to be very lucrative for pharmaceutical companies, as it would generate recurring sales. Recent FDA recommendations, such as approval for a fourth booster dose for those aged 50 or older, suggests we may be moving in this direction. Generic drug makers are expected to continue to struggle due to lower-cost emerging market competition. Despite this, policy risks are on the rise. Lowering drug prices continues to be a bipartisan issue as both parties aim to offer Americans more affordable prices. While this provides uncertainty in the long-term, it is unlikely that legislation will get passed in the near future due to more pressing issues in the political agenda. Year to date through June 3, the S&P Pharmaceuticals Index was up 1.5% vs. a 13.6% decline for the S&P Composite 1500 Index. In 2021, the S&P Pharmaceuticals Index returned a gain of 21.8%, vs. a gain of 26.7% for the S&P Composite 1500.

Sign Up to Receive a Free Special Report That Shows How A+ Investor Grades Can Help You Make Investment Decisions

Grading Johnson & Johnson Stock

Before you choose to buy, sell or hold Johnson & Johnson stock, you’ll want to analyze how it has been graded. Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, making sense of financial ratios, reading income statements and analyzing recent stock movement. To help individual investors decide whether or not to buy (JNJ) stock, AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way that is suitable for investors of all knowledge levels.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A–F grades for each of five key investing factors: value, growth, momentum, earnings revisions and quality. Here, we’ll take a closer look at Johnson & Johnson’s stock grades for value, growth and quality. Learn more about A+ Investor here!

Johnson & Johnson Stock Value Grade

Value Grade:

Metric Rank JNJ Sector Median
Price/Sales 79 4.51 3.40
Price/Earnings 70 30.2 30.2
EV/EBITDA 62 12.9 11.2
Shareholder Yield 7 10.9% (5.0%)
Price/Book Value 84 5.58 2.26
Price/Free Cash Flow 86 61.2 24.8

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection. To decide if Johnson & Johnson stock is a buy or sell, you’ll want to evaluate its fair market price or intrinsic value.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade is derived from a stock’s value score. The value score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81-100 are considered deep value, those with a score between 61-80 are value and so on.

Johnson & Johnson has a Value Score of 25, which is Expensive.

Johnson & Johnson Stock Growth Grade

Growth Grade:

Metric Metric Score JNJ Sector Median
Sales Growth 5yr Ann'l 60 0.9% 11.8%
Sales Increases YoY Last 5 yrs 67 4 of 5 3 of 5
Cash from Operations Ann'l Positive Last 5 yrs 63 5 of 5 1 of 5

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the Growth Score and assign it a letter grade, the percentile ranks for each of the three individual components‐consistency of annual sales growth, five‐year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered Very Weak, while those in the top 20% receive A grades, which are considered Very Strong.

Johnson & Johnson has a Growth Score of 77, which is Strong.

Don’t Miss Your Free Report — Sign Up Here!

Johnson & Johnson Stock Quality Grade

Quality Grade:

Metric Score JNJ Sector Median
Return on Assets (ROA) 97 19.5% (38.9%)
Return on Invested Capital (ROIC) 73 33.1% 21.7%
Gross Income to Assets 71 35.2% 23.0%
Buyback Yield 93 7.9% (5.0%)
Change in Total Liabilities to Assets 81 (7.0%) 0.8%
Accruals to Assets 6 7.4% (8.8%)
Z Double Prime Bankruptcy Risk (Z) Score 82 7.86 1.42
F-Score 94 8 2

Like the Value Grade, AAII’s A+ Investor Quality Grade comes from the percentile rank of key metrics. Specifically, the Quality Grade is the percentile rank of the average of the percentile ranks of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and F-Score.

The score is variable, meaning it can consider all eight measures or, should any of the eight measures not be valid, the remaining measures that are valid. To be assigned a Quality Score, stocks must have a valid (non-null) measure and corresponding ranking for at least four of the eight quality measures.

The Quality Score is used to assess the underlying “quality� of a particular stock. A higher quality stock possesses traits associated with upside potential and reduced downside risk. Backtesting of the Quality Grade shows that stocks with higher grades, on average, outperformed stocks with lower grades over the period of 1998 through 2019.

Stocks receive better grades (higher scores) for having higher scores for the quality subcomponents and worse grades (lower scores) for lower scores for the subcomponents.

Johnson & Johnson has a Quality Score of 97, which is Very Strong.

Johnson & Johnson Stock Momentum Grade

Momentum Grade:

MetricScoreJNJSector Median
Relative Price Strength (Q1) 50 (8.1%)(4.8%)
Relative Price Strength (Q2) 48 (5.8%)(14.5%)
Relative Price Strength (Q3) 60 (3.9%)(19.3%)
Relative Price Strength (Q4) 70 (3.0%)(11.2%)
Relative Price Strength (weighted 4 qtr) 52 (5.8%)(6.2%)

Momentum grades help uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

Johnson & Johnson has a Momentum Score of 52, which is Average.

Other Johnson & Johnson Stock Grades

In addition to Value, Growth, Momentum and Quality, A+ Investor also provides grades for Estimate Revisions.

Invest with Confidence with A+ Investor

AAII’s expansive and robust screening tools like A+ Investor help investors make confident decisions.

The Earnings Estimate Revisions Grade takes into account the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, surprises beget further surprises‐or at least continued sales growth (the exact opposite is generally true, too). AAII’s stock screen that follows the companies with the highest earnings estimate revisions (i.e., the best grades) has a 23.3% backtested annual return since inception, whereas an example screen following those with the worst revisions has a backtested annual return since inception of under 5%.

These 1 key factors, when combined with the above, provide a holistic view into a stock. Further, by joining A+ Investor you can see whether Johnson & Johnson’s stock passes any of our 60+ stock screens that have outperformed the market since their creation.

Is Johnson and Johnson Stock (JNJ) a Good Investment? (5)

Should I Buy Johnson & Johnson Stock?

Overall, Johnson & Johnson stock has a Value Grade of D, Growth Grade of B, Quality Grade of A, Momentum Grade of C .

Whether or not you should buy Johnson & Johnson stock will ultimately depend on your individual goals, risk tolerance and allocation. AAII can help you figure these out and identify which investments align with what works best for you.

Lastly, it’s important to evaluate a stock by comparing it against others in the same industry. Review the table below to see how Johnson & Johnson stock stands up against its competitors. Click into any of the below tickers to see their stock grades for value, momentum, quality and EPS revisions.

Johnson & Johnson (JNJ) Competitors

Companies similar to Johnson & Johnson in the Pharmaceuticals industry.

Company name Ticker Market Cap
Novartis AG (ADR) NVS $205.85Bil
AbbVie Inc ABBV $315.93Bil
Eli Lilly And Co LLY $724.16Bil
MRK $312.78Bil
Novo Nordisk A/S (ADR) NVO $600.15Bil

Johnson & Johnson Stock: Bottom Line

You can use the information about how Johnson & Johnson is graded to determine if you should invest in this stock. However, you should decide whether Johnson & Johnson’s stock is a buy, sell or hold based on a combination of grades, metrics, ratios and U.S. Securities and Exchange Commission (SEC) reports.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets—without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

So, if you’re still on the fence about whether Johnson & Johnson is a buy, sell or hold, you can utilize AAII’s expansive and robust screening tools like A+ Investor to help with your decision.

A+ Investor adds to its qualitative teaching by giving you a powerful data suite that helps you whittle down investment decisions, find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

Is Johnson and Johnson Stock (JNJ) a Good Investment? (6)


Is Johnson and Johnson Stock (JNJ) a Good Investment? (2024)

FAQs

Is Johnson & Johnson a good stock to invest in? ›

Johnson & Johnson as a company is chugging along, generating some decent growth numbers. Its stock trades at a modest 14 times its estimated future earnings (based on analyst estimates). Combined with its high dividend, it can make for an appealing value investment to buy and hold.

Is JNJ dividend safe? ›

Johnson & Johnson (Symbol: JNJ) has been named to the Dividend Channel ''S.A.F.E. 25'' list, signifying a stock with above-average ''DividendRank'' statistics including a strong 3.1% yield, as well as a superb track record of at least two decades of dividend growth, according to the most recent ''DividendRank'' report.

What is the long term forecast for JNJ stock? ›

Johnson & Johnson stock prediction for 1 year from now: $ 176.25 (9.74%) Johnson & Johnson stock forecast for 2025: $ 169.76 (5.70%) Johnson & Johnson stock prediction for 2030: $ 223.95 (39.44%)

Which are the best stocks to invest in 2024? ›

Best stocks in 2024
S.No.NameCMP Rs.
1.Man Infra197.70
2.BLS Internat.364.05
3.Black Box524.00
4.RHI Magnesita601.95
22 more rows

Should i buy Pfizer or Johnson and Johnson stock? ›

Johnson & Johnson: With Return Forecast Of 14%, Pfizer Is A Better Bet.

Is Johnson & Johnson financially healthy? ›

J&J's financial results are considered a bellwether for the broader health sector. The company posted $21.38 billion in total sales for the first three months of 2024, up more than 2% from the same quarter in 2023. The pharmaceutical giant booked net income of $5.35 billion, or $2.20 per share during the quarter.

Is JNJ stock recession proof? ›

This consistent level of demand, diversified product range, strong credit rating and exemplary track record have allowed Johnson & Johnson to build a reputation as a “safe haven” asset during a recession.

Did JNJ dividend increase in 2024? ›

At the new rate, the indicated dividend on an annual basis is $4.96 per share compared to the previous rate of $4.76 per share. The next quarterly dividend is payable on June 4, 2024 to shareholders of record at the close of business on May 21, 2024. The ex-dividend date is May 20, 2024.

Is JNJ going to split up? ›

In 2021, Johnson & Johnson decided to split into two companies. The legacy Johnson & Johnson will focus on pharmaceuticals and medical technology, while a newly formed company named Kenvue (NYSE: KVUE) will concentrate on consumer products.

What is the target price for JNJ in 12 months? ›

The average one-year price target for Johnson & Johnson is $174.90. The forecasts range from a low of $151.50 to a high of $225.75. A stock's price target is the price at which analysts consider it fairly valued with respect to its projected earnings and historical earnings.

Who is the largest shareholder of Johnson and Johnson? ›

Largest shareholders include Vanguard Group Inc, BlackRock Inc., State Street Corp, VTSMX - Vanguard Total Stock Market Index Fund Investor Shares, VFINX - Vanguard 500 Index Fund Investor Shares, Geode Capital Management, Llc, Morgan Stanley, State Farm Mutual Automobile Insurance Co, Jpmorgan Chase & Co, and FXAIX - ...

Should I buy or sell JNJ stock? ›

Johnson & Johnson has a consensus rating of Moderate Buy which is based on 7 buy ratings, 8 hold ratings and 0 sell ratings. The average price target for Johnson & Johnson is $173.14. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.

What is the fair value of JNJ stock? ›

As of 2024-07-31, the Fair Value of Johnson & Johnson (JNJ) is 378.87 USD. This value is based on the Peter Lynch's Fair Value formula. With the current market price of 161.33 USD, the upside of Johnson & Johnson is 134.84%.

What is the 10 year return on Johnson and Johnson stock? ›

Ten Year Stock Price Total Return for Johnson & Johnson is calculated as follows: Last Close Price [ 149.88 ] / Adj Prior Close Price [ 78.55 ] (-) 1 (=) Total Return [ 90.8% ] Prior price dividend adjustment factor is 0.76.

Which is a better stock Johnson & Johnson or Procter & Gamble? ›

P&G and J&J are both excellent choices for income investors. Both have higher dividend yields than the S&P 500's average yield of 1.6%. However, if I had to choose one, I would go with Johnson & Johnson. P&G has done well in business for many years.

What happens to my Johnson and Johnson stock when the company splits? ›

What does the J&J split mean for shareholders? If you currently own shares of Johnson & Johnson, when the company splits, you will own shares of both Johnson & Johnson – which will be the new pharmaceutical/medical device business – as well as shares of Kenvue, the new consumer health business.

Who owns the most Johnson and Johnson stock? ›

Largest shareholders include Vanguard Group Inc, BlackRock Inc., State Street Corp, VTSMX - Vanguard Total Stock Market Index Fund Investor Shares, VFINX - Vanguard 500 Index Fund Investor Shares, Geode Capital Management, Llc, Morgan Stanley, State Farm Mutual Automobile Insurance Co, Jpmorgan Chase & Co, and FXAIX - ...

Is PG stock a buy or sell? ›

Procter & Gamble stock has received a consensus rating of buy. The average rating score is Aa3 and is based on 65 buy ratings, 10 hold ratings, and 0 sell ratings.

Top Articles
How to Delete a Cash App Account
Withdraw payments to your local bank account - Payoneer
13 Easy Ways to Get Level 99 in Every Skill on RuneScape (F2P)
Eric Rohan Justin Obituary
Midway Antique Mall Consignor Access
[2024] How to watch Sound of Freedom on Hulu
South Bend Tribune Online
Https://Gw.mybeacon.its.state.nc.us/App
The Rise of Breckie Hill: How She Became a Social Media Star | Entertainment
Taylor Swift Seating Chart Nashville
Wildflower1967
People Portal Loma Linda
Mflwer
Wausau Marketplace
My Homework Lesson 11 Volume Of Composite Figures Answer Key
Danforth's Port Jefferson
Kirksey's Mortuary - Birmingham - Alabama - Funeral Homes | Tribute Archive
Gayla Glenn Harris County Texas Update
Bella Bodhi [Model] - Bio, Height, Body Stats, Family, Career and Net Worth 
Www.dunkinbaskinrunsonyou.con
Weldmotor Vehicle.com
Water Temperature Robert Moses
Evil Dead Rise Ending Explained
Vivification Harry Potter
Keshi with Mac Ayres and Starfall (Rescheduled from 11/1/2024) (POSTPONED) Tickets Thu, Nov 1, 2029 8:00 pm at Pechanga Arena - San Diego in San Diego, CA
Progressbook Newark
Kristen Hanby Sister Name
Egg Crutch Glove Envelope
Japanese Pokémon Cards vs English Pokémon Cards
Deleted app while troubleshooting recent outage, can I get my devices back?
How to Play the G Chord on Guitar: A Comprehensive Guide - Breakthrough Guitar | Online Guitar Lessons
Metro By T Mobile Sign In
House Of Budz Michigan
Why Holly Gibney Is One of TV's Best Protagonists
Space Marine 2 Error Code 4: Connection Lost [Solved]
Case Funeral Home Obituaries
Best Restaurant In Glendale Az
Evil Dead Rise (2023) | Film, Trailer, Kritik
Emulating Web Browser in a Dedicated Intermediary Box
Joey Gentile Lpsg
Costco Gas Foster City
Nimbleaf Evolution
Ouhsc Qualtrics
Blog Pch
Gelato 47 Allbud
Craigslist Cars And Trucks For Sale By Owner Indianapolis
Spongebob Meme Pic
Ingersoll Greenwood Funeral Home Obituaries
O'reilly's Eastman Georgia
Equinox Great Neck Class Schedule
Latest Posts
Article information

Author: Terence Hammes MD

Last Updated:

Views: 5741

Rating: 4.9 / 5 (69 voted)

Reviews: 92% of readers found this page helpful

Author information

Name: Terence Hammes MD

Birthday: 1992-04-11

Address: Suite 408 9446 Mercy Mews, West Roxie, CT 04904

Phone: +50312511349175

Job: Product Consulting Liaison

Hobby: Jogging, Motor sports, Nordic skating, Jigsaw puzzles, Bird watching, Nordic skating, Sculpting

Introduction: My name is Terence Hammes MD, I am a inexpensive, energetic, jolly, faithful, cheerful, proud, rich person who loves writing and wants to share my knowledge and understanding with you.